Journal
COLLOID AND POLYMER SCIENCE
Volume 296, Issue 7, Pages 1137-1144Publisher
SPRINGER
DOI: 10.1007/s00396-018-4331-x
Keywords
Boron neutron capture therapy; pH gradient; Liposomes; Drug delivery; Dicarba-closo-dodecaborane; Biodistribution: tumor-bearing mice
Categories
Funding
- MEXT-Supported Program for the Strategic Research Foundation at Private Universities [S1001019]
Ask authors/readers for more resources
Various types of boron delivery for boron neutron capture therapy (BNCT) have been studied. To selectively destroy cancer cells, high accumulation and selective delivery of B-10 into tumor tissue are required. In this study, we developed polyboranes from 1,2-dicarba-closo-dodecaborane as boron carriers, and they were encapsulated into liposomes using either the pH gradient or reverse phase evaporation. The encapsulation efficiency of the liposome prepared using the pH gradient was twice as high as that prepared using reverse-phase evaporation. These liposomes, with diameters of either 50 or 100 nm, were injected into the tail veins of tumor-bearing mice to evaluate their biodistribution at 4, 12, and 24 h post-administration. Boron concentration of the polyborane encapsulated liposomes prepared using the pH gradient achieved 110-150 mu g/g of tumor tissue, and the liposomes prepared using the pH gradient were able to achieve an intratumoral B-10 concentration of 20-30 mu g/g without replacing B-11 with B-10. Moreover, this liposome maintained a high B-10 level in the tumor for at least 20 h. Average tumor/blood ratios of liposomes reached 5-15 at 4-24 h after injection. From these results, use of polyborane encapsulated liposomes prepared using the pH gradient for BNCT was suggested.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available